NSD2 and Miyoshi myopathy: There is increasing evidence of myeloma patients that harbor the aforementioned E1099K point mutation, which is not exclusive to ALL patients; also in MM, this mutation leads to NSD2 hyper activation with H3K36me2 global enhancement, H2k27me3 global decrease, and a consequent alteration of the gene expression patterns [81].